CERAMENT is a synthetic injectable and flowable bone void filler that consists of a powder component: 40% hydroxyapatite (HA), 60% calcium sulfate (CaS), and a liquid component, which are mixed to form a paste. The proprietary combination of hydroxyapatite and calcium sulfate is designed to enable CERAMENT to resorb at the same rate that bone forms.
Calcium sulfate acts as a resorbable carrier for hydroxyapatite. Hydroxyapatite has a slow resorption rate and high osteoconductivity promoting bone ingrowth and gives long term structural support to the newly formed bone.
CERAMENT G and CERAMENT V have been developed for situations where there is a risk that the bone healing process may be disturbed by the colonization of microbial organisms. The addition of the antibiotics gentamicin in CERAMENT G and vancomycin in CERAMENT V, inhibit colonization by gentamicin or vancomycin-sensitive microorganisms, in order to protect bone healing.
CERAMENT may be used instead of autograft or allograft, and the characteristics of CERAMENT G and CERAMENT V mean that surgeons can manage bone defects in a more patient-friendly single-stage procedure. CERAMENT G has proven clinical outcomes, with one of the lowest (re)fracture and (re)infection rates of any synthetic bone substitute on the market. Moving to a single-stage from a multi-stage surgical protocol also frees healthcare resources to meet other needs, paving the way for a more cost-effective strategy for hospitals.
These attractive properties have resulted in more than 125,000 patients having been treated with CERAMENT and more than 350 research publications and abstracts of preclinical and clinical studies.